Related Experiment Video
Updated: Mar 23, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.3K
Metformin - For the dermatologist
1Assistant Professor, Department of Dermatology, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
Indian Journal of Pharmacology
|March 22, 2016
Summary
Metformin, an antidiabetic medication, shows significant benefits in various skin conditions like hormonal acne and psoriasis. Its anti-inflammatory and antiandrogenic effects make it a versatile treatment option for dermatologists.
Area of Science:
- Dermatology
- Endocrinology
- Pharmacology
Background:
- Metformin is primarily an antidiabetic drug.
- It influences hyperinsulinemia and possesses antiandrogenic properties.
Purpose of the Study:
- To explore the dermatological applications of metformin beyond its antidiabetic role.
- To highlight metformin's efficacy in treating various cutaneous disorders.
Main Methods:
- Review of existing literature on metformin's use in dermatology.
- Analysis of clinical outcomes in patients with hormonal acne, hidradenitis suppurativa, acanthosis nigricans, hirsutism, psoriasis, cutaneous malignancies, and hyperpigmentary disorders.
Main Results:
- Metformin improves hyperinsulinemia, benefiting hormonal acne, hidradenitis suppurativa, and acanthosis nigricans.
- Antiandrogenic effects aid in managing hirsutism associated with PCOS.
- Systemic and topical metformin show promise in psoriasis, malignancies, and hyperpigmentation.
Conclusions:
- Metformin demonstrates a broad spectrum of efficacy in dermatological conditions.
- Its utility extends from hormonal and inflammatory skin diseases to pigmentary disorders and malignancies.
- Metformin is a valuable therapeutic agent for dermatologists.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
912
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
912
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
841
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
841
01:06Oral Hypoglycemic Agents: Glinides
926
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
926
01:23Dipeptidyl Peptidase 4 Inhibitors
989
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
989
01:22Diabetes Mellitus: Type 2 and Gestational
5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K